Antithrombotic Therapy in Transcatheter Aortic Valve Replacement

Area of Science:

• Cardiology
• Interventional Cardiology
• Vascular Medicine

Background:

• Transcatheter aortic valve replacement (TAVR) is an established treatment for severe aortic stenosis.
• Patients undergoing TAVR often have comorbidities increasing risks for bleeding and cerebrovascular events.
• Current antithrombotic strategies post-TAVR lack definitive evidence-based guidelines.

Purpose of the Study:

• To review the mechanisms underlying bleeding and embolic complications after TAVR.
• To discuss current antithrombotic treatment options for patients undergoing TAVR.
• To explore optimal antithrombotic regimens in TAVR patients, considering oral anticoagulation (OAC) status.

Main Methods:

• Literature review of studies on TAVR and antithrombotic therapy.
• Analysis of mechanisms of bleeding and thromboembolic events in TAVR patients.
• Discussion of existing clinical evidence and guidelines regarding antithrombotic use.

Main Results:

• TAVR is a viable alternative for severe aortic stenosis in high-risk and intermediate-risk patients.
• Increased risk of bleeding and cerebrovascular complications necessitates careful antithrombotic management.
• Optimal antithrombotic regimen remains unclear, requiring individualized patient assessment.

Conclusions:

• Antithrombotic therapy is crucial for managing TAVR-related complications.
• Further research is needed to establish evidence-based guidelines for antithrombotic treatment post-TAVR.
• Personalized antithrombotic strategies are essential for optimizing outcomes in TAVR patients.